Eagle Pharmaceuticals Inc. has issued a voluntary recall on four Lots ofÂ Argatroban Injection because vials of the drug may contain “visible particulates.”

The company said in a press release announcing the recall that it has not received any reports of adverse events as a result of the defect in its product. The company said the recall is being conducted after it received one complaint from a customer who noticed visible material in a vial of the drug.

Visible particulates in injection drugs could present numerous problems for patients who rely on these drug treatments. If this matter enters the patient through the injection, it could cause internal injuries or serious infections that could lead to unexpected death. In previous recalls involving this defect, the material could range from dust or glass particles from the vials.